Novo Nordisk
The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.